JP MORGAN/CALL/BECTON DICKINSON AND CO./290/0.1/17.01.25 Stock

Warrant

DE000JL1MJ15

Market Closed - Bid/Ask 03:06:58 2024-05-21 EDT After market 13:58:22
0.66 EUR +4.76% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./290/0.1/17.01.25 0.64 -3.03%
Current month-17.11%
1 month-21.25%
Date Price Change
24-05-21 0.66 +4.76%
24-05-20 0.63 -5.97%
24-05-17 0.67 -9.46%
24-05-16 0.74 +8.82%
24-05-15 0.68 -5.56%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 03:06 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL1MJ1
ISINDE000JL1MJ15
Date issued 2023-04-05
Strike 290 $
Maturity 2025-01-17 (241 Days)
Parity 10 : 1
Emission price 1.8
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.76
Lowest since issue 0.63
Spread 0.06
Spread %8.96%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW